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OBJECTIVES This study describes the outcomes of patients from the Antiarrhythmics Versus Implantable
Defibrillators (AVID) Study Registry to determine how the location of ventricular arrhythmia
presentation influences survival.
BACKGROUND Most studies of cardiac arrest report outcome following out-of-hospital resuscitation. In
contrast, there are minimal data on long-term outcome following in-hospital cardiac arrest.
METHODS The AVID Study was a multicenter, randomized comparison of drug and defibrillator
strategies to treat life-threatening ventricular arrhythmias. A Registry was maintained of all
patients with sustained ventricular arrhythmias at each study site. The present study includes
patients who had AVID-eligible arrhythmias, both randomized and not randomized. Patients
with in-hospital and out-of-hospital presentations are compared. Data on long-term
mortality were obtained through the National Death Index.
RESULTS The unadjusted mortality rates at one- and two-year follow-ups were 23% and 31.1% for
patients with in-hospital presentations, and 10.5% and 16.8% for those with out-of-hospital
presentations (p , 0.001), respectively. The adjusted mortality rates at one- and two-year
follow-ups were 14.8% and 20.9% for patients with in-hospital presentations, and 8.4% and
14.1% for those with out-of-hospital presentations (p , 0.001), respectively. The adjusted
long-term relative risk for in-hospital versus out-of-hospital presentation was 1.6 (95%
confidence interval [CI] 1.3–1.9).
CONCLUSIONS Compared with patients with out-of-hospital presentations of life-threatening ventricular
arrhythmias not due to a reversible cause, patients with in-hospital presentations have a worse
long-term prognosis. Because location of ventricular arrhythmia presentation is an indepen-
dent predictor of long-term outcome, it should be considered as an element of risk
stratification and when planning clinical trials. (J Am Coll Cardiol 1999;34:1111–6) © 1999
by the American College of Cardiology
Most studies of cardiac arrest report the outcomes of
patients who experience cardiac arrhythmias out-of-hospital
(1–12). Furthermore, many studies limit inclusion to pa-
tients with ventricular fibrillation (VF) on arrival of para-
medics (1–3), and some describe the results only for patients
with coronary artery disease (4). Thus, the immediate and
the long-term outcomes of patients suffering out-of-
hospital cardiac arrest and surviving to leave the hospital are
well known. In contrast, outcomes following in-hospital
cardiac arrest are less well studied (13–18), and there are
minimal data on the long-term outcome of in-hospital
cardiac arrest survivors (14,16,17). Furthermore, the rela-
tion of the location of cardiac arrest on long-term outcome
is unknown.
Arguments may be made that the survivors of in-hospital
resuscitation could have either better or worse prognoses
than those with out-of-hospital presentations. On the one
hand, prompt resuscitation of patients already in the hos-
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pital should reduce immediate morbidity due to the cardiac
arrest itself and possibly improve the chance for long-term
survival. On the other hand, inpatients may have important
comorbidities that negatively affect survival (15,16). Con-
versely, patients with out-of-hospital presentations may be
expected to have worse outcomes owing to a prolonged time
to the initiation of advanced cardiac life support and
defibrillation (4,5,8–10). Still, those who do survive may be
selected for better long-term outcomes because they lived to
be admitted to the hospital.
When the Antiarrhythmias Versus Implantable Defibril-
lators (AVID) Study was planned, patients resuscitated
from both in-hospital and out-of-hospital life-threatening
ventricular arrhythmias were considered eligible for ran-
domization if they had appropriate arrhythmias and were
candidates for both implantable cardioverter-defibrillator
(ICD) and antiarrhythmic drug therapy (19,20). As the trial
progressed, it became evident during the assessment that a
significant number of patients with in-hospital presenta-
tions of ventricular arrhythmias were being randomized.
The present study describes the outcomes of patients
included in the AVID Study Registry to determine how the
location of ventricular arrhythmia presentation influences
survival. The results may influence the choice of inclusion
criteria for future secondary prevention trials to manage
life-threatening ventricular arrhythmias. It may also help to
risk-stratify these patients better, thus helping to determine
their future treatments.
METHODS
Study design. The AVID Study was a multicenter, ran-
domized comparison of antiarrhythmic drug treatment
(mostly amiodarone) and ICD implantation to manage
patients resuscitated from life-threatening ventricular ar-
rhythmias not due to transient or reversible causes. Eligible
arrhythmias included 1) VF; 2) sustained ventricular tachy-
cardia (VT) with syncope; and 3) sustained VT with an
ejection fraction of #0.40, and symptoms suggestive of
severe hemodynamic compromise. The trial design and
primary end-point paper have been published (19,20). It is
interesting to note that the location of index ventricular
arrhythmia presentation was not a factor in eligibility for
randomization. Each participating institution had approval
from its Institutional Review Board for conduct of the
study. All patients who underwent randomization gave
written informed consent.
As part of the study design, a registry was maintained of
all patients with sustained ventricular arrhythmias at each
study site. It included not only patients who were random-
ized, but also 1) patients who were eligible for the AVID
Study but did not undergo randomization because of refusal
or exclusions to participation; 2) patients with arrhythmias
who did not qualify for randomization in the trial because
they were thought to be less serious, such as stable VT, or
VT or VF with a transient or correctable cause; and 3)
patients with unexplained syncope. The present study in-
cludes all patients, both randomized and not randomized,
who had AVID-eligible arrhythmias (VF; sustained VT
with syncope; or sustained VT with an ejection fraction of
#0.40, and symptoms suggestive of severe hemodynamic
compromise).
Patients were excluded from the Registry and random-
ization in the AVID Study if the index arrhythmia occurred
in-hospital within five days of myocardial infarction (de-
fined by electrocardiographic changes or enzyme elevations
in accordance with local standards), coronary angioplasty,
coronary artery bypass grafting, or if the patient had
undergone prior ICD implantation. Other exclusions in-
cluded life expectancy less than one year, severe neurologic
damage, chronic bacterial infection, severe neurologic im-
pairment, class IV congestive heart failure, anticipated
cardiac transplantation or the presence of an intra-aortic
balloon pump, other device or drug necessary for hemody-
namic support. Additional trial exclusions included coronary
revascularization (either surgical or percutaneous) planned
or performed since the index arrhythmia event and left
ventricular ejection fraction .0.40; arrhythmia or aneurysm
surgery planned or performed since the index event, index
event on amiodarone (or exposure to amiodarone in last six
months, unless the total dose was ,10 g, exposure ,2 weeks,
or level #0.2 mg/ml); contraindication to amiodarone, long
QT syndrome, atrial fibrillation, or other supraventricular
tachycardia requiring class I or III antiarrhythmic drug
therapy; and bradycardia or heart block without an im-
planted pacemaker.
All Registry patients were followed through hospital
discharge. Data on long-term mortality were obtained
through the National Death Index as of December 31,
1996.
Statistical analyses. Univariate comparisons of the charac-
teristics of patients presenting with out-of-hospital versus
in-hospital life-threatening ventricular arrhythmias were
based on t tests for continuous variables or chi-square tests
for discrete variables. Survival rates were estimated by the
Kaplan-Meier method. Survival was measured with time
zero being the day of the index ventricular arrhythmia.
Adjusted relative risk estimates were based on the propor-
tional hazards survival model. Covariates included in the
model were age; race; gender; arrhythmia type; history of
atrial fibrillation, congestive heart failure, diabetes, syncope,
coronary artery disease, revascularization, prior VT; left
Abbreviations and Acronyms
AVID Study 5 Antiarrhythmics Versus Implantable
Defibrillators Study
ICD 5 implantable cardioverter-defibrillator
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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ventricular ejection fraction; antiarrhythmic drug use at the
time of the index event; and discharge treatments (ICD,
beta-adrenergic blocking agent, diuretics, digitalis, amioda-
rone, other antiarrhythmic drug and warfarin). A p value of
0.05 was used as the significance level for the multivariate
analyses.
RESULTS
The study group included 2,674 patients in the AVID
Registry resuscitated from primary life-threatening ventric-
ular arrhythmias, 806 (30%) that occurred in-hospital and
1,868 (70%) that occurred out-of-hospital. All had experi-
enced VF (n 5 1,351, 51%), VT with syncope (n 5 593,
22%), or hemodynamically compromising VT and a left
ventricular ejection #0.40 (n 5 730, 27%). None of these
arrhythmias was due to acute myocardial infarction or a
reversible cause. Twenty-one percent of the patients with
in-hospital presentations had been admitted for noncardiac
reasons, 12% had events within five days of an invasive
procedure not related to the arrhythmia itself or to correc-
tion of ischemia and 87% were in monitored setting at the
time of their arrhythmia event. Ventricular fibrillation was
the index arrhythmia in 992 (53.1%) of patients with
out-of-hospital presentations and 359 (44.5%) with in-
hospital presentation (p , 0.001).
Baseline characteristics. Patients resuscitated from in-
hospital events were older, more likely to be ethnic minor-
ities and female and had lower left ventricular ejection
fractions than did those with out-of-hospital presentations
(Table 1). Patients with in-hospital presentations more
frequently had histories of congestive heart failure, atrial
fibrillation, diabetes, prior VT, syncope, coronary artery
revascularization by either surgical or catheter-based inter-
ventions and coronary artery disease. Finally, they were
more likely to be taking an antiarrhythmic drug at the time
of their index arrhythmia. There was no significant differ-
ence in their respective histories of prior VF, prior myocar-
dial infarction, cigarette use or the incidence of nonischemic
cardiomyopathy.
Discharge treatments. Patients with in-hospital arrhyth-
mia presentations were more likely to be discharged receiv-
ing a diuretic, digoxin, amiodarone, another antiarrhythmic
drug or warfarin (Table 2). Those resuscitated from an out-
of-hospital arrhythmia were more likely to have received a
beta-blocker or an ICD. There was no difference in the use of
angiotensin-converting enzyme inhibitors, calcium channel
blockers, or revascularization following the index event.
Survival. The in-hospital mortality rate for patients with
in-hospital presentations was 4.6% and with out-of-hospital
presentations 1.1% (p , 0.001) (Table 3). The unadjusted
late mortality rates at one- and two-year follow-ups were
23.0% and 31.1% for patients with in-hospital presenta-
tions, and 10.5% and 16.8% for those with out-of-hospital
presentations (p , 0.001), respectively (Fig. 1). The ad-
justed late mortality rates at one- and two-year follow-ups
were 14.8% and 20.9% for patients with in-hospital presen-
tations, and 8.4% and 14.1% for those with out-of-hospital
presentations (p , 0.001), respectively (Fig. 2). The ad-
justed long-term relative risk for in-hospital versus out-of-
hospital presentations was 1.6 (95% CI 1.3–1.9).
DISCUSSION
Compared with patients with out-of-hospital presentations
of life-threatening ventricular arrhythmias not due to a
reversible cause, patients with in-hospital presentations are
sicker and have a worse long-term prognosis. It is important
to note that the difference in survival remained after
adjusting for all the measured baseline predictors and
discharge therapies.
Table 1. Baseline Characteristics by Location of Index Ventricular Arrhythmia Presentation
In-Hospital
Presentation
(n 5 806)
Out-of-Hospital
Presentation
(n 5 1,868) p Value
Age (yr, mean value 6 SD) 65 6 11 64 6 12 , 0.001
White (%) 83 90 , 0.001
Female gender (%) 27 23 0.03
LV ejection fraction (mean value 6 SD) 0.31 6 0.13 0.34 6 0.15 , 0.001
History of
Congestive heart failure (%) 55 40 , 0.001
Atrial fibrillation (%) 33 22 , 0.001
Diabetes (%) 31 18 , 0.001
Ventricular tachycardia (%) 20 14 , 0.001
Syncope (%) 15 10 , 0.001
CABG/PTCA (%) 37 32 0.01
Coronary artery disease (%) 80 76 0.007
AAD at presentation (%) 18 13 , 0.001
AAD 5 antiarrhythmic drug; CABG 5 coronary artery bypass grafting; LV 5 left ventricular; PTCA 5 percutaneous coronary
angioplasty; SD 5 standard deviation.
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In-hospital presentation. Survival to hospital discharge is
low following in-hospital cardiac arrest (13,14,16,17).
However, the ability to draw conclusions from small studies
is limited because they include patients suffering cardiac
arrest from a variety of causes such as trauma, drug overdose
and myocardial infarction (13–18). Although long-term
outcome in survivors of in-hospital resuscitation is not often
described, Bedell et al. (16) reported in 1983 a 14%
discharge rate (41 patients) of 294 patients resuscitated in a
university teaching hospital. Long-term mortality of pa-
tients who survived to hospital discharge was high (25%) at
six months’ follow-up. Some older studies also included
patients who suffered cardiac arrest in unique locations such
as the operating room and cardiac catheterization labora-
tory, and therefore were specially selected (14,15). In the
AVID Registry, patients with certain reversible or transient
causes and acute ischemia were excluded.
Out-of-hospital presentation. The 83.1% two-year sur-
vival rate for patients with out-of-hospital presentations of
life-threatening ventricular arrhythmias and who were
treated with antiarrhythmic drugs, ICDs, and a combina-
tion of therapies in the AVID Registry was similar to the
81.6% two-year survival rate for patients randomized to
receive ICDs in the main AVID Study (20). None of these
patients had evidence for acute ischemia or a reversible or
transient cause of their arrhythmia. The strict eligibility
criteria make a comparison to earlier studies difficult because
many of these other studies included patients with VF
associated with acute myocardial infarction (1–4,6,11). In
some studies (12), the actual incidence of acute myocardial
infarction is not indicated, but it is stated that most patients
had complaints, such as chest pain, before cardiac arrest,
suggesting that ischemia was present in a large proportion.
Role of prompt resuscitation. Survival rates range from
43% in Seattle, Washington, for bystander-initiated cardio-
pulmonary resuscitation (21) to as low as 0.8% for African-
Americans suffering cardiac arrest in Chicago (22). Varia-
tions in survival from cardiac arrest, whether occurring
in-hospital or out-of-hospital, depend on myriad factors
including differences in case definition and community
demographics (23,24), whether or not arrest is witnessed
(8,24), whether or not resuscitation is begun quickly
(9,21,25,26) and whether or not first responders are trained
in defibrillation, advanced life support and use of automatic
defibrillators (8,26). Problems in gaining access to arrested
patients in the out-of-hospital setting represents a signifi-
cant impediment to survival (22). When automatic external
defibrillators are used, rates of survival-to-hospital discharge
as high as 49% have been reported for patients treated for
VF by police and paramedics (26) and 26% for patients
treated in an airline cardiac arrest program (27). One might
expect that an in-hospital life-threatening ventricular ar-
rhythmia presentation would increase the chance for early
intervention, successful resuscitation and perhaps long-term
survival.
Table 2. Discharge Treatments by Location of Ventricular Arrhythmia Presentation
In-Hospital
Presentation
(n 5 806)
Out-of-Hospital
Presentation
(n 5 1,868) p Value
Diuretic (%) 60 46 , 0.001
Digoxin (%) 48 40 , 0.001
Beta-blocker (%) 24 29 0.005
Implantable cardioverter-defibrillator (%) 43 53 , 0.001
Amiodarone (%) 49 40 , 0.001
Other antiarrhythmic drug (%) 8 5 0.009
Warfarin (%) 32 24 , 0.001
ACE inhibitor (%) 61 61 NS
Calcium channel blocker (%) 14 14 NS
Revascularization after index event (%) 14 14 NS
AAD 5 antiarrhythmic drug; ACE 5 angiotensin-converting enzyme.
Table 3. Mortality Rate by Location of Presentation
In-Hospital
Mortality Rate
Late Mortality Rate
Adjusted
Relative Risk1 Year 2 Year
In-Hospital Presentation
(n 5 806)
4.6% 23.0% 31.1% 1.6 (95% CI 1.3–1.9)
Out-of-Hospital Presentation
(n 5 1,868)
1.1% 10.5% 16.8%
p Value , 0.001 , 0.001 , 0.001
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The importance of location. Early defibrillation is
thought to increase the chance for resuscitation from cardiac
arrests that occur out-of-hospital, and to improve long-term
outcome for those who survive (21,25,28). Thus, the chance
for successful resuscitation from cardiac arrests that occur
in-hospital might be expected to be even greater because of
the availability of prompt resuscitation. Nevertheless, a
statement for health care professionals regarding in-hospital
resuscitation emphasizes that, in some hospitals, cardiac
arrest response teams must bring defibrillators from remote
locations (29). Thus, early defibrillation may not be
achieved even in the hospital setting. Furthermore, in-
hospital arrhythmias can occur in nonmonitored settings
where time to discovery of arrest might be quite prolonged.
Of note, 87% of our in-hospital presentations occurred
while the patients were being monitored. Nevertheless,
patients with in-hospital presentations in the AVID Reg-
istry had a fourfold greater in-hospital mortality than did
those with out-of-hospital presentations (Table 3).
Study strengths and limitations. The present study pro-
vides contemporary data regarding long-term survival after
successful resuscitation from life-threatening ventricular
arrhythmias. Only patients with primary arrhythmic causes
were included.
Only survivors of life-threatening ventricular arrhythmias
who were candidates for both drug and ICD therapy were
included in this study. Patients with out-of-hospital presen-
tations who died before reaching the hospital, or soon after
hospital admission, and those who were not candidates for
AVID therapies, patients who survived in-hospital presen-
tations but were not candidates for both AVID therapies, or
who died soon after their cardiac arrest and resuscitation,
patients with acute myocardial infarction or ischemia and
patients too ill to be included in the AVID Registry were
not followed. Thus, because the patients were highly se-
lected, the study’s strength of having a very clearly defined
and specific population is similarly a weakness.
Furthermore, there may be a problem of selection bias for
both groups that may be opposite: Whereas sicker patients
were already in the hospital and hence had worse prognoses,
healthier patients were both not hospitalized yet well
enough to survive out-of-hospital resuscitation. As noted,
in-hospital mortality for patients with in-hospital presenta-
tions was significantly greater than for those with out-of-
hospital presentations.
Finally, although the adjusted analysis shows the persis-
tence of a worse outcome for patients with in-hospital
presentations, many unaccounted variables could explain the
difference. Not only were patients with in-hospital presen-
tations sicker than were those with out-of-hospital presen-
tations but the relative contributions of concomitant disease,
location of presentation or other unknown variables on
outcome are unknown. One possibility is that outpatients
had prolonged VT as their initiating arrhythmia that pro-
vided some hemodynamic stability before degeneration to
VF, thereby increasing the chance for successful resuscitation.
Data on the effect of type of arrhythmia management on
outcome stratified by location of presentation were not
analyzed for this cohort because treatment was not random-
ized in all patients, and some of the nonrandomized patients
received neither ICD nor drug therapy. Such an analysis for
those randomized in the main study was done, and in fact
showed no difference in survival. However, the groups were
small, thereby limiting power of the analysis.
Implications of the present study. The present study
reports long-term survival data for patients with life-
threatening ventricular arrhythmias treated with contempo-
rary drugs and devices stratified by the location of arrhyth-
Figure 2. Adjusted survival of patients in the AVID Registry with
in-hospital versus out-of-hospital presentations of AVID-eligible
ventricular arrhythmias. Time zero is the date of the index
arrhythmia.
Figure 1. Unadjusted survival of patients in the AVID Registry
with in-hospital versus out-of-hospital presentations of AVID-
eligible ventricular arrhythmias. Time zero is the date of the index
arrhythmia.
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mia presentation. Given the poor prognosis for survivors of
in-hospital cardiac arrest previously reported (13,14,16,17),
it should not be surprising that our patients with in-hospital
presentations had higher long-term mortality rates com-
pared to survivors of out-of-hospital presentations. However,
patients were not entered in the AVID Registry unless they
were candidates for both ICD and drug treatment and were
thought to have a survival probability of at least one year. That
their survival probabilities were still imperfect, even with ICD
therapy, attests to the need for further work to improve survival
for patients with life-threatening ventricular arrhythmias.
Patients in the present study with in-hospital presenta-
tions of life-threatening ventricular arrhythmias carried
greater burdens of concomitant disease than did those with
out-of-hospital presentations. Thus, improved management
of ventricular arrhythmias in the hospital may not influence
long-term outcome.
In addition, patients with in-hospital presentations in this
study were more likely to be treated with amiodarone than
with an ICD, perhaps further decreasing their chance for
long-term survival. Regardless, that survival can be so
influenced by location of presentation and concomitant
disease emphasizes the importance of randomization in
clinical trials, and that comparison with nonconcurrent,
nonrandomized data may be misleading if unsuspected
confounders such as location of presentation are not con-
sidered. In the main AVID Study, the results were not
affected because randomization was done irrespective of
location of presentation and equal numbers of patients with
either presentation were included in each treatment arm.
However, because location of presentation is an indepen-
dent predictor of long-term outcome, it should now be
considered when deciding on clinical trial inclusion and
design issues in the future. Finally, the location of arrhyth-
mia presentation could be considered for risk stratification.
Reprint requests and correspondence: AVID CTC, 1107 NE
45th Street, Room 505, Seattle, Washington, 98105-4689. E-
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